Concomitant antiplatelet therapy in Table 1. Baseline characteristics Figure 1. The effect of sex and APT use on clinical outcomes Annualised event rate, %/year anticoagulated transcatheter aortic valve Female (n = 658) Male (n = 719) (95% CI)a No APT APT...
More
Concomitant antiplatelet therapy in Table 1. Baseline characteristics Figure 1. The effect of sex and APT use on clinical outcomes Annualised event rate, %/year anticoagulated transcatheter aortic valve Female (n = 658) Male (n = 719) (95% CI)a No APT APT No APT APT Parameter P-valuea P-valuea implantation patients with atrial fibrillation: (n = 270) (n = 388) (n = 283) (n = 436) Hazard Interaction Outcome No APT APT ratio Age at enrolment, years 82.6 ± 5.2 82.6 ± 5.5 1.0 82.2 ± 5.0 81.1 ± 5.6 0.01 P-valuec,d (95% CI)b Impact of sex on bleeding and ischaemic Ethnicity, White Weight, kg 219 (81.1) 68.5 ± 17.3 324 (83.5) 71.0 ± 18.5 0.5 0.08 236 (83.4) 78.4 ± 15.4 367 (84.2) 81.4 ± 15.9 0.7 0.01 NACE Male 13.47 (10.18–17.50) 18.08 (14.88–21.78) 1.33 (0.97–1.84) 1.0 events in ENVISAGE-TAVI AF BMI, kg/m2 CrCl,b mL/min 27.8 ± 6.2 52.2 ± 22.1 27.9 ± 6.4 55.8 ± 24.6 0.8 0.06 27.3 ± 4.5 61.2 ± 25.8 27.6 ± 4.8 62.2 ± 22.8 0.4 0.6 Female 14.58 (11.02–18.94) 19.44 (15.80–23.67) 1.32 (0.95–1.83) I
Less
